ArticleCancer reports (Hoboken, N.J.)2025
Exploration of the Prognostic Markers of Multiple Myeloma Based on Cuproptosis-Related Genes.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- RNA-Based Therapeutic Strategies in Multiple Myeloma: From Molecular Targets to Delivery and Clinical Translation.International journal of molecular sciences · 2026Review
- The Role of Genomics in the Development and Treatment of Multiple Myeloma: Understanding the Challenges and Opportunities.OncoTargets and therapy · 2026Review
- Beyond the bone marrow: a review of therapeutic approaches for extramedullary disease in multiple myeloma and the significance of MRD assessment.Journal of medicine and life · 2025Review
- Cuproptosis: A Review on Mechanisms, Role in Solid and Hematological Tumors, and Association with Viral Infections.Mediterranean journal of hematology and infectious diseases · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe investigation of cuproptosis in relation to tumor development has been limited, particularly in multiple myeloma (MM), indicating the need for further research. Our study aimed to examine the impact of cuproptosis-related genes (CRGs) on the prognosis of MM.
methodsUsing the datasets, we filtered cuproptosis score-related differentially expressed genes (CRDEGs) by overlapping the DEGs between the MM and normal groups and between the high and low cuproptosis score groups. Additionally, key module genes were identified through weighted gene co-expression network analysis. A univariate Cox algorithm and multivariate Cox analysis were employed to obtain biomarkers of MM and build a prognostic model before conducting independent prognostic analysis.
resultsA total of 59 CRDEGs were filtered, demonstrating their involvement in the COPII vesicle coat and endoplasmic reticulum protein processing, and protein processing in the endoplasmic reticulum. Six prognosis-related biomarkers (PARP1, EDEM3, SEC23A, RSL24D1, TTC37, and SRP72) were obtained, and a prognostic model was developed. The performance of the model was verified using a test cohort (GSE136324 dataset) and a validation cohort (GSE24080 dataset). Risk score, age, albumin, International Staging System (ISS) score, and β2-microglobulin (B2M) were found to be significant predictors of prognosis independently.
conclusionAs a result of this investigation, a set of six biomarkers associated with cuproptosis (PARP1, EDEM3, SEC23A, RSL24D1, TTC37, and SRP72) were screened to provide a basis for predicting the prognosis of MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.